

33. (Previously Presented) A method of treating a human or animal with cancer or an immune disease comprising administering to the human or animal a composition comprising two or more biologically-active factors admixed with or bound to a colloidal metal, wherein at least one of the biologically-active factors is a target molecule capable of binding a receptor on a cell membrane.

34. (Previously Presented) The method of Claim 33 wherein the biologically active factor is selected from the group consisting of Interleukin-1 α ("IL-1 α "), Interleukin-1 β ("IL-1 β "), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-9 ("IL-9"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor ("CSF"), Monocyte-Macrophage CSF, Granulocyte CSF, vascular epithelial growth factor ("VEGF"), Angiogenin, transforming growth factor alpha ("TGF α "), transforming growth factor beta ("TGF β "), heat shock proteins, carbohydrate moieties of blood groups, RH factors, fibroblast growth factor, chemotherapeutic drugs, AZT, nucleotides, DNA, RNA, sense, antisense, cancer, cell specific antigens, hormones, antibodies, and immunotherapeutic drugs.

35. (Previously Presented) The method of Claim 33 wherein the target molecule is selected from the group consisting of Interleukin-1 ("IL-1"), Interleukin-2 ("IL-2"), Interleukin-3 ("IL-3"), Interleukin-4 ("IL-4"), Interleukin-5 ("IL-5"), Interleukin-6 ("IL-6"), Interleukin-7 ("IL-7"), Interleukin-8 ("IL-8"), Interleukin-10 ("IL-10"), Interleukin-11 ("IL-11"), Interleukin-12 ("IL-12"), Interleukin-13 ("IL-13"), Type I Interferon, Type II Interferon, Tumor Necrosis Factor ("TNF α "), Transforming Growth Factor- β ("TGF β "), vascular epithelial growth factor ("VEGF"), receptor proteins, glucose, glycogen, phospholipids, monoclonal and/or polyclonal antibodies, and transforming growth factor ("TGF α ").

REMARKS

This amendment is responsive to the Notice of Non-Compliant Amendment mailed May 16, 2008. Claims 1-26 were missing from the Listing of Claims in the Response filed April 17, 2008. A corrected Listing of Claims section providing the status of claims 1-26 in compliance with 37 C.F.R. § 1.121 is submitted herewith. No new matter is added.

CONCLUSION

The foregoing is submitted as a full and complete response to the Notice of Non-Compliant Amendment mailed May 16, 2008, and early and favorable consideration of the claims is requested. If the Examiner believes any informalities remain in the application that may be corrected by Examiner's amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned agent at (404) 572-2447 is respectfully solicited.

No further fees are believed to be due in connection with this response. However, the Commissioner is hereby authorized to charge any underpayment or credit any overpayment of fees to Deposit Account No. 11-0980.

Respectfully submitted,

/F. BRENT NIX/

F. Brent Nix
Reg. No. 59,004

KING & SPALDING LLP
1180 Peachtree Street, N.E.
Atlanta, Georgia 30309-3521
Telephone (404) 572-4600
Facsimile (404) 572-5134